肿瘤穿透肽iRGD在肿瘤靶向纳米递药治疗中的研究进展

恶性肿瘤是目前严重威胁人类生命健康的重大疾病之一，随着对恶性肿瘤研究的深入，越来越多的抗肿瘤药物被研发应用并取得显著的成效，但是由于复杂的肿瘤微环境，抗肿瘤药物常难以渗透至肿瘤组织深部，导致生物利用度低，抗肿瘤作用减弱。肿瘤穿透肽（tumor-penetrating peptide）iRGD化学连接在纳米载体表面或者与纳米载体联合给药，促进药物渗透至肿瘤组织深部有效发挥抗肿瘤作用，是目前肿瘤靶向治疗领域中备受关注的研究方向之一。本文回顾并总结了iRGD在抗肿瘤靶向纳米递药治疗中的研究进展，这些研究结果都显示了肿瘤穿透肽iRGD在肿瘤靶向治疗中拥有良好的应用前景。

Research progress of tumor-penetrating peptide iRGD in targeted drug-carrying nanoparticles delivery

Malignant tumor is one of the major diseases that seriously threaten human life at present.With the deepening of cancer research，more and more anti-tumor drugs have been developed and achieved remarkable results.Many solid tumor types have a generally poor prognosis，in part because the pathological abnormalities of tumor tissue prohibit the penetration of anti-tumor drugs into tumor vasculature，leading to poor bioavailability.The recent development of the tumor-penetrating peptide iRGD that is covalently conjugated on the nanocarriers' surface or co-administered with nanocarriers becomes a popular approach for tumor targeting.In this paper，we reviewed the recent progress in iRGD-mediated drug-carrying nanoparticles and prospected its further application in tumor targeting therapy.